|
Post by kc on Jul 21, 2020 17:12:49 GMT -5
What we all know is afrezza and the CGM are like peanut butter and jelly. Then again so are afrezza and the 680 as it will be with the 780 too. We also know Medtronic did well with Al's last company. Why did Galindo come to MNKD? You answered your own question. Lol....... Covid is an interesting situation. Will a company like Medtronic know now to monetize a novel drug delivery system? I guess we know they did it with Mini-Med...... Medtronic has lots of cash and experience in every area of healthcare. You can bet they know how to monetize something as novel as Technosphere. They are into selling products that have a high consumable nature.
|
|
|
Post by kc on Jul 20, 2020 20:59:46 GMT -5
|
|
|
Post by kc on Jul 20, 2020 20:31:50 GMT -5
|
|
|
Post by kc on Jul 20, 2020 20:27:03 GMT -5
This was the pet project of Alejandro Galindo! We are very pleased to offer this added flexibility for those who rely on our therapies for their diabetes management needs,” Alejandro Galindo, president of Medtronic's Intensive Insulin Management division, said in a statement. You just have to wonder if medtronic is looking to add a new device to the diabetes arsenal 😉
|
|
|
Post by kc on Jul 20, 2020 19:08:11 GMT -5
Medtronic needs their man on board at MannKind. Time will tell. Like the person who joined MannKind from Amgen.
|
|
|
Post by kc on Jul 20, 2020 10:19:42 GMT -5
So with his Pedegree to Medtronic makes you wonder what is focus might be going forward.
Let the speculation begin!
|
|
|
Post by kc on Feb 28, 2020 10:24:24 GMT -5
Sadly I don’t think that MannKind will be sustainable unless the BOD takeS some drastic action and make a big paradigm shift in pricing of Afrezza. BOD Needs to give payers a reaso to prescribe Afrezza. Payers will only pay for the cheapest most compliant drug. We now have five years proof that players are shunning Mannkind One comment from CEO Castagna did bother me. When asked about payer coverage, he stated that ~80% of commercial payers cover Afrezza but then, when asked about possible future plans to improve payer coverage, Castagna's response included the remark "we're okay with the P.A." (Reminder: PA = prior authorization and approval is required for patient to be covered for Afrezza). This indicates one of two obstacles to unrestricted coverage are still being faced: - Payers give preferred status to other brands of rapid-acting insulin that compete against Afrezza, or;
- Payers consider insulin to be dangerous and therefore require ALL brands of rapid-acting insulin to be burdened with the PA requirement.
Slide 6 illustrates that one of the MannKind's 2020 Strategies is to "Focus on Placing Key Bets to Drive Wider Afrezza Adoption" is the creation of a Specialty Pharmacy Network that is hoped will provide:
- Reimbursement support
- Pharmacy fulfillment support
- Patient persistency tactics (e.g. texts, emails, phone calls)
This is troublesome to me as MannKind apparently has capitulated and has decided a good option is to basically put the burden of dealing with the payer onto the patient. Reading through all the hype, what's this CEO is saying here is that patient is likely to be denied coverage and the physician doesn't have time or won't make the time to become a patient advocate with payers. It seems that the CEO believes that it will be beneficial to teach the patients communication tactics to use against the payer. Does Castagna really think that the majority of patients are going to suddenly become assertive when denied coverage for Afrezza by their plan managers? IMO, only a fraction of the patients will be persistent. The same applies for physicians. The 2020 Strategy relies heavily on organic growth rather than tactics associated with disrupting the diabetes market. IMO, if this is the strategy, then stockholders can expect slow adoption of Afrezza to continue.
|
|
|
Post by kc on Feb 28, 2020 9:48:58 GMT -5
The reason why this product has never gained any traction it’s too costly for the type one and type two diabetics. insurance companies our unwilling to pay the high price for such a good product. If the company is to survive the market the product it will have to be a total paradigm shift in the way that Afrezza is marketed. While none of us know what the cost of goods to produce Afrezza might be. We know it’s priced very high equal to the best selling insulin drugs on the market.
If you want to get on a better schedule you need to cut the price 50% and hope that you don’t go out of business while you try to build a new base of users. show the pharmaceutical industry that you’re prepared to take it directly to the consumer with good pricing.
The Board of Directors needs to look carefully how to change this dynamic. with our current pricing we will never make the right schedules to be an every day non-boutique drug for Medicare, Tricare,even Medicaid.
Formularies are chosen by the insurance companies based on prices and Afrezza is priced too high to make the cut. Evidenced by the fact that we keep hearing the complaint that we get new initiations but people cannot stay on Afrezza.
Time for the drastic paradigm shift and make this a product Affordable for all.
Selling in other markets like Brazil and India may prove this case.
|
|
|
Post by kc on Feb 28, 2020 0:41:23 GMT -5
It’s all about pricing. The product cost too much.
|
|
|
Post by kc on Feb 28, 2020 0:37:25 GMT -5
The reason why this product has never gain any traction it’s too costly for the type one and type two diabetics. insurance companies our unwilling to pay the high price for such a good product. If the company is to survive the market the product it will have to be a total paradigm shift in the way that Afrezza is marketed. While none of us know what the cost of goods to produce Afrezza might be. We know it’s priced very high equal to the best selling insulin drugs on the market. If you want to get on a better schedule you need to cut the price 50% and hope that you don’t go out of business while you try to build a new base of users. show the pharmaceutical industry that you’re prepared to take it directly to the consumer with good pricing. Formularies are chosen by the insurance companies based on prices and Afrezza it is priced too high.
|
|
|
Post by kc on Feb 27, 2020 21:26:58 GMT -5
I still like their graphic illustration of what they are doing. Wouldn’t it be Great if they were part of the solution along with MannKind in a vaccine. Even if experimental. “Inhaled Powder” technovax.com/inhaled-powder-vaccines/Vaccines “Shelf-Stable, Self-Inhaled, Powderized” VLP Vaccines. TechnoVax and MannKind Corp. have combined their respective technologies to create a Powder Formulation of VLP Influenza Vaccine for Intrapulmonary Self-Delivery by Inhalation. No refrigeration is required, and because it is potentially self-administered public exposure is limited. In the event of an emerging pandemic the vaccine could be easily distributed to the population, greatly reducing the spread of the virus! Advantages Extended Shelf Life and Elimination of Cold Chain results in improved distribution costs and inventory management. Best Route of Immunization (mucosal surface – respiratory tract) Increased Patient Acceptance (inhaled vs. injection) inhaled-powder VLP’s are combined with FPDK Excipient Particles for optimized airflow delivery using the Cricket Inhalation Device. “Inhaled Powder” Vaccines “Shelf-Stable, Self-Inhaled, Powderized” VLP Vaccines. TechnoVax and MannKind Corp. have combined their respective technologies to create a Powder Formulation of VLP Influenza Vaccine for Intrapulmonary Self-Delivery by Inhalation. No refrigeration is required, and because it is potentially self-administered public exposure is limited. In the event of an emerging pandemic the vaccine could be easily distributed to the population, greatly reducing the spread of the virus! Advantages Extended Shelf Life and Elimination of Cold Chain results in improved distribution costs and inventory management. Best Route of Immunization (mucosal surface – respiratory tract) Increased Patient Acceptance (inhaled vs. injection) inhaled-powder VLP’s are combined with FPDK Excipient Particles for optimized airflow delivery using the Cricket Inhalation Device.
|
|
|
Post by kc on Feb 24, 2020 19:19:02 GMT -5
|
|
|
Post by kc on Feb 24, 2020 19:16:55 GMT -5
|
|
|
Post by kc on Feb 24, 2020 19:16:29 GMT -5
|
|
|
Post by kc on Feb 24, 2020 19:16:17 GMT -5
|
|